title: Long-term results of kidney transplantation from HCV-positive donors.
abstract: BACKGROUND
  Due to the shortage of organs for transplantation, procurement of kidneys from marginal donors is inevitable. Not infrequently, these donors are infected with hepatitis C virus (HCV).
  
  
  OBJECTIVE
  We sought to determine the effect of transplanting kidneys from anti-HCV-positive donors to anti-HCV-positive recipients.
  
  
  METHODS
  Among 765 procedures between 1994 and 2006, 259 kidney recipients were anti-HCV-positive, including 60 who received kidneys from anti-HCV-positive donors (HCV(+)/HCV(+) group) and the others, from seronegative donors (HCV(-)/HCV(+) group). The control group of 506 seronegative recipients received kidneys from seronegative donors (HCV(-)/HCV(-) group). All kidneys from anti-HCV-positive donors were preserved with machine perfusion. We investigated recipient liver function tests (LFTs; alanine aminotrasferase, aspartate aminotransferase; alkaline phosphatase, and bilirubin), graft survival, and patient survival.
  
  
  RESULTS
  No significant difference was observed between the groups among the biochemistry results (LFTs, creatinine at 5 years). No significant differences, were observed in patient survival, graft survival, or number of patients returning to dialysis.
  
  
  CONCLUSIONS
  Transplantation of kidneys from HCV-positive donors to HCV-positive recipients did not influence long-term liver function, or long-term renal allograft function. This strategy enhances the availability of transplantation as means of end-stage renal disease treatment.
authors.affiliation: Department of General and Transplantation Surgery, Medical University of Wroclaw, Wroclaw, Poland. tomekasprzyk@esculap.pl
authors.forename: T
authors.initials: T
authors.lastname: Kasprzyk
authors.forename: A
authors.initials: A
authors.lastname: Kwiatkowski
authors.forename: M
authors.initials: M
authors.lastname: Wszola
authors.forename: K
authors.initials: K
authors.lastname: Ostrowski
authors.forename: R
authors.initials: R
authors.lastname: Danielewicz
authors.forename: P
authors.initials: P
authors.lastname: Domagala
authors.forename: P
authors.initials: P
authors.lastname: Malkowski
authors.forename: S
authors.initials: S
authors.lastname: Fesolowicz
authors.forename: R
authors.initials: R
authors.lastname: Nosek
authors.forename: J
authors.initials: J
authors.lastname: Czerwinski
authors.forename: J
authors.initials: J
authors.lastname: Trzebicki
authors.forename: M
authors.initials: M
authors.lastname: Durlik
authors.forename: L
authors.initials: L
authors.lastname: Paczek
authors.forename: D
authors.initials: D
authors.lastname: Patrzalek
authors.forename: W
authors.initials: W
authors.lastname: Rowinski
authors.forename: A
authors.initials: A
authors.lastname: Chmura
mesh_terms: D001663:Bilirubin / Q000097:blood; D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D006085:Graft Survival; D006526:Hepatitis C / Q000635:transmission*; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology*; D008111:Liver Function Tests; D012189:Retrospective Studies; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors; D014019:Tissue Donors
chemical_list: D003404:Creatinine; D001663:Bilirubin